Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383214 · ClinicalTrials.gov registry record · Phase 3
Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
A Phase 3 study, sponsored by UCB Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 54
- Enrollment target
NCT00383214: Clinical Trial Phase 3 study, sponsored by UCB Pharma.
NCT00383214 is a Phase 3 study that was terminated before completion, run by UCB Pharma. The registered enrollment target is 54 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00383214, a Phase 3 study, was terminated before completion, sponsored by UCB Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of Epratuzumab with standard treatments for patients with SLE.
Interventions
- OTHER Placebo
- DRUG Epratuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Why NCT00383214 stopped before completion
NCT00383214 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00383214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00383214 about?
NCT00383214 is a clinical study titled "Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)". The purpose of this study is to evaluate the safety and efficacy of Epratuzumab with standard treatments for patients with SLE.
What is the current status of trial NCT00383214?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 54 participants. The study started on 2005-05. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00383214?
The interventions under investigation include: Placebo (OTHER), Epratuzumab (DRUG).
Who is sponsoring clinical trial NCT00383214?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00383214's enrollment target sits among peer trials
54 1838th of 2000 higher than 162 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia